Search

everythinglearnresearchcommunity

for

Search:↓

Using finasteride and peptides, including GHK-Cu, improved hair thickness and regrowth. The user also used a KLOW blend and CJC/IPA for better sleep and recovery.

Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

The effects of Finasteride on hair loss and its side-effects, such as aching balls. The user has been taking it for two years with no changes to the symptom.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

Researching the effectiveness of the hair loss treatment Pyril in comparison to other treatments such as Minoxidil, Finasteride, and RU58841. Replies suggest that users often fail to provide updates on their experience with Pyril.

Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.

The conversation is about the effectiveness of peptides for hair loss and the user considering using GHK-Cu, CJC-1295, and BPC-157 for treatment.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

An increase in libido associated with the use of Pyri, and a discussion about how it may be working comparably to other hair loss treatments such as RU58841, Finasteride and Minoxidil.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

Peptides like GHK-Cu are discussed for hair regrowth, with mixed results; some users report no regrowth, while others notice thicker hair. Topical application is common, and proper sourcing and mixing are emphasized.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

The conversation discusses using GHK-Cu copper peptide from Bulk Naturals for hair loss, comparing its price and quality to Peptide Sciences. Concerns about the product's legitimacy are mentioned, but COA documents are available.

This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

The conversation is about the effectiveness and safety of a hair loss treatment called Pyri, with users discussing its availability and comparing it to other treatments like RU58841, fluridil, and alfatradiol. Some users are waiting for FDA approval before using Pyri, while others share their positive experiences with RU58841 and suggest additional treatments with minimal side effects.